Skip to main content
ARTV
NASDAQ Life Sciences

RA Capital Lifts Artiva Stake to 37.9% with $5.7M in Fresh Buys

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$10.13
Mkt Cap
$492.198M
52W Low
$2.22
52W High
$14.53
52W Position info
356% above low
Off High info
30% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ARTV has more than doubled off its 52-week low of $2.22.

Summary

RA Capital Management raised its stake in Artiva Biotherapeutics to 37.9% through $5.7 million in open market purchases, extending a pattern of heavy accumulation by major investors.


Key Events · Ownership and Investor Activity · ARTV

  • RA Capital Acquires 604K Shares

    In open market transactions between June 16 and July 23, 2026, RA Capital bought 604,333 shares at prices ranging from $8.62 to $10.00, for a total outlay of approximately $5.7 million.

  • Stake Rises to 37.9%

    After the purchases, RA Capital's aggregate ownership climbed to 18,415,956 shares, representing 37.9% of Artiva's outstanding common stock.

  • Continued Accumulation Post-Offering

    The buying continues a pattern of heavy accumulation by RA Capital and other insiders following a $300 million public offering in May 2026, reinforcing confidence in the company's clinical prospects.

  • Purchases Near Current Price

    The most recent purchases were made at prices up to $10.00, close to the current stock price of $10.13, indicating the fund's willingness to buy at market levels.


Analysis · ARTV · Life Sciences

Between June 16 and July 23, 2026, RA Capital—a major institutional investor with board representation—acquired an additional 604,333 shares for roughly $5.7 million, paying as much as $10.00 per share. The buying lifts its total position to 18.4 million shares, or 37.9% of the company. Coming on the heels of a $300 million public offering in May and a series of large insider purchases, the spree signals deep institutional conviction in Artiva's autoimmune pipeline. With the latest trades executed near the current $10.13 level, the fund appears to see further upside.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARTV was trading at $10.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $492.2M. The 52-week trading range was $2.22 to $14.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARTV - Latest Insights

ARTV
Nov 09, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.22
Real-time Price: $4.00 info
Change: -$0.225 (-5%) info
Market Cap: $197.482M info
ARTV
Oct 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.09
Real-time Price: $4.00 info
Change: -$0.095 (-2%) info
Market Cap: $197.482M info
ARTV
Oct 27, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
10
Price at Filing: $6.30
Real-time Price: $4.00 info
Change: -$2.30 (-37%) info
Market Cap: $197.482M info
ARTV
Oct 01, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $4.00 info
Change: -$3.26 (-45%) info
Market Cap: $197.482M info
ARTV
Aug 06, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.58
Real-time Price: $4.00 info
Change: -$7.59 (-66%) info
Market Cap: $197.482M info